Comunicados de prensa Vertex Pharmaceuticals — News Releases Biotech — Feed RSS y monitoreo en vivo
PPN World sigue el feed RSS de Vertex Pharmaceuticals — News Releases en tiempo real — 3 comunicados indexados en los últimos 30 días, el más reciente llegó hace 6 d. Síguelo con alertas de búsquedas guardadas, resúmenes con IA y búsqueda de texto completo, o conecta la URL RSS de abajo a tu propio lector.
URL del feed RSS de Vertex Pharmaceuticals — News Releases
https://investors.vrtx.com/rss/news-releases.xml?items=15Sobre este feed
Vertex Pharmaceuticals — News Releases forma parte de los más de 1000 feeds de comunicados que PPN World monitorea de forma continua — una fuente en inglés centrada en el sector Biotech, clasificada bajo «Estados Unidos» en nuestro índice por país. Cada comunicado se deduplica, se geolocaliza y se enriquece con un resumen de IA, y puedes añadir alertas de búsquedas guardadas sobre cualquier palabra clave que publique. En los últimos 30 días, Vertex Pharmaceuticals — News Releases ha publicado 3 comunicados.
Cómo seguir los comunicados de Vertex Pharmaceuticals — News Releases
- Copia la URL del feed RSS de Vertex Pharmaceuticals — News Releases que aparece arriba.
- Pégala en cualquier lector RSS (Feedly, Inoreader, NetNewsWire…) para recibir el feed sin procesar.
- O sigue Vertex Pharmaceuticals — News Releases en PPN World para añadir deduplicación, alertas de búsquedas guardadas y resúmenes con IA en los más de 1000 feeds.
Últimos comunicados de Vertex Pharmaceuticals — News Releases
- Vertex to Announce Second Quarter 2026 Financial Results on August 3rdhace 6 d
BOSTON --(BUSINESS WIRE)--Jul. 7, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets…
- Vertex to Acquire Crinetics Pharmaceuticalshace 7 d
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY ®, Crinetics’ recently launched, fi…
- Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemiahace 12 d
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia - - Approximately 5,500 additional childr…
- Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissionshace 33 d
- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consist…
- Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conferencehace 38 d
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of
- Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10hace 40 d
BOSTON --(BUSINESS WIRE)--Jun. 3, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Dr.…
- Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathyhace 42 d
- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 – BOSTON --(BUSINESS WIRE)--Jun. 1, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announc…
Los comunicados más recientes de esta fuente se transmiten en vivo para los miembros de PPN World.